AXSM Axsome Therapeutics Inc.

4.71
+0.11  (2%)
Previous Close 4.60
Open 4.65
Price To book 6.63
Market Cap 111491828
Shares 23,671,301
Volume 39,324
Short Ratio 4.12
Av. Daily Volume 110,195

SEC filingsSee all SEC filings

  1. 8-K - Current report 171187070
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171186808
  3. 8-K - Current report 171147613
  4. 424B5 - Prospectus [Rule 424(b)(5)] 171147519
  5. 8-K - Current report 171088968

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 initiation announced July 17, 2017.
AXS-05 ADVANCE-1
Agitation in patients with Alzheimer’s disease (AD)
Initiated July 2015. Interim efficacy analysis due late December 2017 or early January 2018.
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 initiated March 2016. Top-line data due 1H 2018.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 commenced March 2016. Interim efficacy analysis due late December 2017 or early January 2018.
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 initiation contingent upon resources.
AXS-02
Chronic Low Back Pain Associated with Modic Changes

SEC Filings

  1. 8-K - Current report 171187070
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171186808
  3. 8-K - Current report 171147613
  4. 424B5 - Prospectus [Rule 424(b)(5)] 171147519
  5. 8-K - Current report 171088968
  6. 8-K - Current report 171079089
  7. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171019928
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018573
  9. 8-K - Current report 171018027
  10. 8-K - Current report 17983073